ライフサイエンスコーパス: was administered orally

1 ARRY-063 was administered orally to ovalbumin (OVA) sensitized and cha

2 Capecitabine (825, 1,000, or 1,250 mg/m(2)) was administered orally twice daily on days 1 to 14 every 3 w

3 COL-3 was administered orally once daily at one of two doses (group

4 Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day

5 was administered once a day on days 1 to 28 and abexinostat was administered orally twice a day on days 1 to 5, 8 to 12,

6 Alisertib was administered orally at 50 mg twice daily for 7 days in 21

7 Alisertib was administered orally in 21-day cycles at the recommended p

8 d potent and selective P2X3 and P2X2/3 receptor antagonist, was administered orally to rats and found to produce highly s

9 Arimoclomol was administered orally, in drinking water, from symptom onse

10 AZD1775 was administered orally twice per day over 2.5 days per week

11 Then, to assess its efficacy in vivo, BTKB66 was administered orally to mice for 7 days before subjecting

12 Dexamethasone 40 mg daily was administered orally on days 1, 8, 15, and 22 of each cycl

13 Erlotinib was administered orally daily to groups of at least three ass

14 Erlotinib was administered orally once daily to cohorts of three to six

15 Everolimus was administered orally at 10 mg daily and letrozole was admi

16 Everolimus was administered orally at a daily dose of 2.1, 3, 5, or 6.5

17 In nonclinical studies, fidaxomicin was administered orally at approximately 1 g/kg/d to dogs for

18 gefitinib on topotecan CNS penetration, 200 mg/kg gefitinib was administered orally 1 hour before 4 mg/kg topotecan i.v.

19 SR largely increased in diabetic subjects only when glucose was administered orally (37.8 +/- 14.9 vs 68.3 +/- 22.8 nmol;

20 nt irreversible methionine aminopeptidase type 2 inhibitor, was administered orally every other day at 1, 5, or 10 mg/kg.

21 ur phase I study, the intravenous formulation of irinotecan was administered orally daily for 5 days for 2 consecutive we

22 Lapatinib was administered orally twice daily at escalating doses start

23 LCL161 was administered orally, once weekly, on a 21-day cycle to ad

24 Lenalidomide was administered orally at 25 mg on days 1 through 21 of a 28

25 olimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily.

26 Lonafarnib was administered orally twice daily at dose levels of 70, 90,

27 Lorlatinib was administered orally to patients at doses ranging from 10

28 Ibrutinib at a daily dose of 420 mg was administered orally until disease progression or the deve

29 Dipyridamole 75 mg was administered orally three times daily during the FU admin

30 Pazopanib 800 mg was administered orally once daily.

31 Sunitinib (25, 37.5, or 50 mg) was administered orally once daily on three dosing schedules:

32 with leukemia or myelodysplastic syndromes (MDS), MGCD0103 was administered orally 3 times weekly without interruption.

33 ML120B was administered orally twice daily, either prophylactically

34 Darapladib 160 mg or placebo monotherapy was administered orally once daily for 3 months, and patients

35 In this phase 2 open-label study, 400 mg nilotinib was administered orally twice daily to 280 patients with Phil

36 in a continuous fashion via subcutaneous implant, whereas P was administered orally in a cyclic fashion.

37 In the dose-escalation phase (n = 47), panobinostat was administered orally thrice weekly every week in combinati

38 AQX-1125 (450 mg daily) or placebo was administered orally for 7 days.

39 In groups PROB and LIP/PROB, the PROB was administered orally by addition to the drinking water of

40 PT2385 was administered orally at twice-per-day doses of 100 to 1,80

41 Quizartinib was administered orally at escalating doses of 12 to 450 mg/d

42 SM16 was administered orally in formulated chow.

43 Sorafenib was administered orally at 400 mg twice daily on a continuous

44 Temozolomide was administered orally within 60 minutes of the end of the 1

45 part, we evaluated escalations in the dose of PLX3397 that was administered orally in patients with solid tumors (dose-e

46 Treatment was administered orally 5 d/wk for 3 months.

47 (13)C-glycerol tripalmitin was administered orally as an independent measure of CM TAG m

48 WAY-202196 or control (vehicle) was administered orally in doses ranging from 1.5 to 50 mg/kg

49 Vorinostat was administered orally daily starting at 180 mg/m(2)/d with

50 A-988315 (20 or 60 mg/kg) or water was administered orally 90 min before retention testing, foll